CAS 942398-84-7|Amiselimod hydrochloride

Introduction：Basic information about CAS 942398-84-7|Amiselimod hydrochloride, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Amiselimod hydrochloride BiologicalActivity
3. Chemical & Physical Properties
4. Synonyms

Common Name	Amiselimod hydrochloride
CAS Number	942398-84-7	Molecular Weight	413.902
Density	/	Boiling Point	/
Molecular Formula	C₁₉H₃₁ClF₃NO₃	Melting Point	/
MSDS	/	Flash Point	/

Names

Name	amiselimod hydrochloride
Synonym	More Synonyms

Amiselimod hydrochloride BiologicalActivity

Description	Amiselimod hydrochloride is a novel sphingosine 1-phosphate receptor-1 (S1P1) modulator, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators.target: S1P1In vivo: After oral administration of amiselimod or fingolimod at 1 mg/kg, the concentration of amiselimod-P in rat heart tissue was relatively lower than that of fingolimod-P, potentially contributing to the minimal cardiac effects of amiselimod. Amiselimod-P showed potent selectivity for S1P1 , high selectivity for S1P5 , minimal agonist activity for S1P4 , no distinct agonist activity for S1P2 or S1P3 , and approximately 5-fold weaker GIRK activation than fingolimod-P. [1] Amiselimod 0·2 mg and 0·4 mg significantly reduced the total number of gadolinium-enhanced T1-weighted lesions. [2]
Related Catalog	Signaling Pathways >>GPCR/G Protein >>LPL ReceptorResearch Areas >>Cancer
References	[1]. Sugahara K et al. Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. Br J Pharmacol. 2016 Oct 7. [2]. Kappos L et al. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016 Oct;15(11):1148-59.

Description

Amiselimod hydrochloride is a novel sphingosine 1-phosphate receptor-1 (S1P1) modulator, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators.target: S1P1In vivo: After oral administration of amiselimod or fingolimod at 1 mg/kg, the concentration of amiselimod-P in rat heart tissue was relatively lower than that of fingolimod-P, potentially contributing to the minimal cardiac effects of amiselimod. Amiselimod-P showed potent selectivity for S1P1 , high selectivity for S1P5 , minimal agonist activity for S1P4 , no distinct agonist activity for S1P2 or S1P3 , and approximately 5-fold weaker GIRK activation than fingolimod-P. [1] Amiselimod 0·2 mg and 0·4 mg significantly reduced the total number of gadolinium-enhanced T1-weighted lesions. [2]

Related Catalog

Signaling Pathways >>GPCR/G Protein >>LPL ReceptorResearch Areas >>Cancer

References

[1]. Sugahara K et al. Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. Br J Pharmacol. 2016 Oct 7.

[2]. Kappos L et al. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016 Oct;15(11):1148-59.

Chemical & Physical Properties

Molecular Formula	C₁₉H₃₁ClF₃NO₃
Molecular Weight	413.902
Exact Mass	413.194458
InChIKey	GEDVJGOVRLHFQG-UHFFFAOYSA-N
SMILES	CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F.Cl
Storage condition	2-8℃

Synonyms

MT-1303

UNII-AY898D6RU1

AMISELIMOD HYDROCHLORIDE

2-Amino-2-{2-[4-(heptyloxy)-3-(trifluorométhyl)phényl]éthyl}-1,3-propanediol, chlorhydrate (1:1)

2-Amino-2-{2-[4-(heptyloxy)-3-(trifluormethyl)phenyl]ethyl}-1,3-propandiolhydrochlorid (1:1)

2-Amino-2-{2-[4-(heptyloxy)-3-(trifluoromethyl)phenyl]ethyl}-1,3-propanediol hydrochloride (1:1)

1,3-Propanediol, 2-amino-2-[2-[4-(heptyloxy)-3-(trifluoromethyl)phenyl]ethyl]-, hydrochloride (1:1)

Amiselimod HCl

Recommended......